RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vir Biotechnology Stock

Vir Biotechnology Net Income 2024

Vir Biotechnology Net Income

-467.23 M USD

Ticker

VIR

ISIN

US92764N1028

WKN

A2PS0P

In 2024, Vir Biotechnology's profit amounted to -467.23 M USD, a -24.04% increase from the -615.06 M USD profit recorded in the previous year.

The Vir Biotechnology Net Income history

YEARNET INCOME (undefined USD)
2029e144.91
2028e-306.37
2027e-307.3
2026e-501.83
2025e-520.12
2024e-467.23
2023-615.06
2022515.8
2021528.6
2020-298.7
2019-174.7
2018-115.9
2017-69.9

Vir Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vir Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vir Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vir Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vir Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vir Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vir Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vir Biotechnology’s growth potential.

Vir Biotechnology Revenue, EBIT and net profit per share

DateVir Biotechnology RevenueVir Biotechnology EBITVir Biotechnology Net Income
2029e1.53 B undefined0 undefined144.91 M undefined
2028e245.87 M undefined-578.73 M undefined-306.37 M undefined
2027e214.6 M undefined-693.37 M undefined-307.3 M undefined
2026e44.94 M undefined-641.65 M undefined-501.83 M undefined
2025e32.76 M undefined-652.14 M undefined-520.12 M undefined
2024e71.63 M undefined-549.9 M undefined-467.23 M undefined
202386.18 M undefined-684.31 M undefined-615.06 M undefined
20221.62 B undefined833.1 M undefined515.8 M undefined
20211.1 B undefined420.8 M undefined528.6 M undefined
202076.4 M undefined-297 M undefined-298.7 M undefined
20198.1 M undefined-178 M undefined-174.7 M undefined
201810.7 M undefined-118.7 M undefined-115.9 M undefined
20172.7 M undefined-80.8 M undefined-69.9 M undefined

Vir Biotechnology stock margins

The Vir Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vir Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vir Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vir Biotechnology's sales revenue. A higher gross margin percentage indicates that the Vir Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vir Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vir Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vir Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vir Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vir Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vir Biotechnology Margin History

Vir Biotechnology Gross marginVir Biotechnology Profit marginVir Biotechnology EBIT marginVir Biotechnology Profit margin
2029e96.79 %0 %9.49 %
2028e96.79 %-235.38 %-124.61 %
2027e96.79 %-323.1 %-143.2 %
2026e96.79 %-1,427.89 %-1,116.73 %
2025e96.79 %-1,990.49 %-1,587.51 %
2024e96.79 %-767.73 %-652.32 %
202396.79 %-794.04 %-713.69 %
202290.95 %51.56 %31.92 %
202193.99 %38.42 %48.26 %
202096.79 %-388.74 %-390.97 %
201996.79 %-2,197.53 %-2,156.79 %
201896.79 %-1,109.35 %-1,083.18 %
201796.79 %-2,992.59 %-2,588.89 %

Vir Biotechnology Aktienanalyse

What does Vir Biotechnology do?

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Vir Biotechnology's Profit Margins

The profit margins of Vir Biotechnology represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Vir Biotechnology's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Vir Biotechnology's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Vir Biotechnology's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Vir Biotechnology’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Vir Biotechnology stock

How much profit has Vir Biotechnology made this year?

Vir Biotechnology has made -467.23 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -24.04% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Vir Biotechnology publish its earnings?

Vir Biotechnology publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Vir Biotechnology?

The profits of Vir Biotechnology are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Vir Biotechnology?

You can learn more about the earnings of Vir Biotechnology by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Vir Biotechnology pay?

Over the past 12 months, Vir Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vir Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of Vir Biotechnology?

The current dividend yield of Vir Biotechnology is .

When does Vir Biotechnology pay dividends?

Vir Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vir Biotechnology?

Vir Biotechnology paid dividends every year for the past 0 years.

What is the dividend of Vir Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vir Biotechnology located?

Vir Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vir Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vir Biotechnology from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Vir Biotechnology pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Vir Biotechnology in the year 2023?

In the year 2023, Vir Biotechnology distributed 0 USD as dividends.

In which currency does Vir Biotechnology pay out the dividend?

The dividends of Vir Biotechnology are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vir Biotechnology

Our stock analysis for Vir Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vir Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.